Watson-Amgen to Develop Biosimilars - Analyst Blog

By
A A A

Watson Pharmaceuticals Inc. ( WPI ) and Amgen Inc. ( AMGN ) recently announced a collaboration agreement for the worldwide development and commercialization of oncology antibody biosimilar medicines.

According to the agreement, Amgen will be responsible for developing, manufacturing and initially commercializing the products. Watson Pharma will contribute $400 million towards the co-development of the biosimilars, which will include the provision of development support, along with sharing product development risks. Moreover, Watson Pharma will use its significant expertise for the commercialization and marketing of products, together with effectively managing the lifecycle of the biosimilar products.

The products developed under the collaboration will be sold under a joint Amgen/Watson label. Also, as a part of the collaboration, Watson Pharma will initially receive royalties and sales milestones from product revenues. Meanwhile, the terms of the collaboration prohibit the production of any biosimilars of Amgen's proprietary products.

We believe that this deal will help expand Watson Pharma's biosimilar and generic portfolio, which will help drive the company's long-term growth.

An Eventful Month

So far it has been quite an eventful month for Watson Pharma. Earlier during the month, Watson Pharma, along with partner Antares Pharma Inc. ( AIS ), announced the US approval of topical oxybutynin gel 3%. The US Food and Drug Administration (FDA) approved the drug for treating patients suffering from overactive bladder (OAB). By virtue of an exclusive licensing agreement, Watson Pharma plans to launch the drug in 2012.

Also this month, Watson Pharma announced the launch of a generic version of Teva Pharmaceutical Industries Ltd. 's ( TEVA ) LoSeasonique. The drug is used for the prevention of pregnancy. The launch of the generic drug took place as a part of a settlement agreement between the two companies.

We currently have an Outperform recommendation on Watson Pharma. The stock carries a Zacks #2 Rank (Buy rating) in the short-run.


 
ANTARES PHARMA ( AIS ): Free Stock Analysis Report
 
AMGEN INC ( AMGN ): Free Stock Analysis Report
 
TEVA PHARM ADR ( TEVA ): Free Stock Analysis Report
 
WATSON PHARMA ( WPI ): Free Stock Analysis Report
 
Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: AIS , AMGN , TEVA , WPI

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Russell’s One Good Reason
Russell’s One Good Reason           
Tammy’s One Good Reason
Tammy’s One Good Reason             
Lisa’s One Good Reason
Lisa’s One Good Reason              

Stocks

Referenced

Most Active by Volume

87,324,760
  • $7.31 ▲ 22.04%
79,329,227
  • $17.16 ▲ 0.76%
74,153,988
  • $8.87 ▼ 5.84%
49,177,672
  • $34.01 ▲ 4.39%
44,197,901
  • $101.40 ▲ 1.38%
43,197,735
  • $11.70 ▲ 3.36%
42,712,021
  • $74.99 ▲ 1.19%
42,423,171
  • $108 ▲ 0.95%
As of 10/31/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com